 | • レポートコード：MRC23Q38889 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（2-3日） • 産業分類：医療機器 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のウイルス様粒子（VLP）ワクチン市場について調査・分析し、世界のウイルス様粒子（VLP）ワクチン市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン）、用途別セグメント分析（肝炎、HPV、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Merck and Co.、GlaxoSmithKline、Pfizer、Dynavax Technologies、Sanofi、Wantai BioPharm、Serum Institute of India、Bharat Biotech、LG Chem、VBI Vaccinesなどが含まれています。 世界のウイルス様粒子（VLP）ワクチン市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ウイルス様粒子（VLP）ワクチン市場規模を推定する際に考慮しました。本レポートは、ウイルス様粒子（VLP）ワクチンの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ウイルス様粒子（VLP）ワクチンに関するビジネス上の意思決定に役立てることを目的としています。 ・ウイルス様粒子（VLP）ワクチン市場の概要 - 製品の定義 - ウイルス様粒子（VLP）ワクチンのタイプ別セグメント - 世界のウイルス様粒子（VLP）ワクチン市場規模：タイプ別分析（弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン） - ウイルス様粒子（VLP）ワクチンの用途別セグメント - 世界のウイルス様粒子（VLP）ワクチン市場規模：用途別分析（肝炎、HPV、その他） - 世界のウイルス様粒子（VLP）ワクチン市場規模予測（2018年-2029年） - ウイルス様粒子（VLP）ワクチンの平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - ウイルス様粒子（VLP）ワクチン市場の競争状況およびトレンド ・ウイルス様粒子（VLP）ワクチンの地域別市場規模 - 北米のウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - アメリカのウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - ヨーロッパのウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - アジア太平洋のウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - 中国のウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - 日本のウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - 韓国のウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - インドのウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - オーストラリアのウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - 中南米のウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） - 中東・アフリカのウイルス様粒子（VLP）ワクチン市場規模（2018年-2029年） ・タイプ別セグメント：弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン - 世界のウイルス様粒子（VLP）ワクチンのタイプ別販売量（2018年-2023年） - 世界のウイルス様粒子（VLP）ワクチンのタイプ別売上（2018年-2023年） - 世界のウイルス様粒子（VLP）ワクチンのタイプ別価格 ・用途別セグメント：肝炎、HPV、その他 - 世界のウイルス様粒子（VLP）ワクチンの用途別販売量（2018年-2023年） - 世界のウイルス様粒子（VLP）ワクチンの用途別売上（2018年-2023年） - 世界のウイルス様粒子（VLP）ワクチンの用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Merck and Co.、GlaxoSmithKline、Pfizer、Dynavax Technologies、Sanofi、Wantai BioPharm、Serum Institute of India、Bharat Biotech、LG Chem、VBI Vaccines ・産業チェーンと販売チャネルの分析 - ウイルス様粒子（VLP）ワクチン産業チェーン分析 - ウイルス様粒子（VLP）ワクチンの主要原材料 - ウイルス様粒子（VLP）ワクチンの販売チャネル - ウイルス様粒子（VLP）ワクチンのディストリビューター - ウイルス様粒子（VLP）ワクチンの主要顧客 ・ウイルス様粒子（VLP）ワクチン市場ダイナミクス - ウイルス様粒子（VLP）ワクチンの業界動向 - ウイルス様粒子（VLP）ワクチン市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
VLP stands for virus-like particles. Virus-like particles are molecules that mimic viruses but are not infectious. They are a very effective way of creating vaccines against diseases such as human papillomavirus (HPV), hepatitis B, malaria, and more.
Highlights
The global Virus-like Particles (VLPs) Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Virus-like Particles (VLPs) Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Virus-like Particles (VLPs) Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Virus-like Particles (VLPs) Vaccine include Merck and Co., GlaxoSmithKline, Pfizer, Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India, Bharat Biotech and LG Chem, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Virus-like Particles (VLPs) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Virus-like Particles (VLPs) Vaccine.
The Virus-like Particles (VLPs) Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Virus-like Particles (VLPs) Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Virus-like Particles (VLPs) Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Merck and Co.
GlaxoSmithKline
Pfizer
Dynavax Technologies
Sanofi
Wantai BioPharm
Serum Institute of India
Bharat Biotech
LG Chem
VBI Vaccines
Segment by Type
Live-Attenuated Vaccines
Inactivated Vaccines
Recombinant Vaccines
Toxoid Vaccines
Segment by Application
Hepatitis
HPV
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Virus-like Particles (VLPs) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Virus-like Particles (VLPs) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Virus-like Particles (VLPs) Vaccine Market Overview
1.1 Product Overview and Scope of Virus-like Particles (VLPs) Vaccine
1.2 Virus-like Particles (VLPs) Vaccine Segment by Type
1.2.1 Global Virus-like Particles (VLPs) Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Live-Attenuated Vaccines
1.2.3 Inactivated Vaccines
1.2.4 Recombinant Vaccines
1.2.5 Toxoid Vaccines
1.3 Virus-like Particles (VLPs) Vaccine Segment by Application
1.3.1 Global Virus-like Particles (VLPs) Vaccine Market Value by Application: (2023-2029)
1.3.2 Hepatitis
1.3.3 HPV
1.3.4 Others
1.4 Global Virus-like Particles (VLPs) Vaccine Market Size Estimates and Forecasts
1.4.1 Global Virus-like Particles (VLPs) Vaccine Revenue 2018-2029
1.4.2 Global Virus-like Particles (VLPs) Vaccine Sales 2018-2029
1.4.3 Global Virus-like Particles (VLPs) Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Virus-like Particles (VLPs) Vaccine Market Competition by Manufacturers
2.1 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Virus-like Particles (VLPs) Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Virus-like Particles (VLPs) Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Virus-like Particles (VLPs) Vaccine, Product Type & Application
2.7 Virus-like Particles (VLPs) Vaccine Market Competitive Situation and Trends
2.7.1 Virus-like Particles (VLPs) Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Virus-like Particles (VLPs) Vaccine Players Market Share by Revenue
2.7.3 Global Virus-like Particles (VLPs) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Virus-like Particles (VLPs) Vaccine Retrospective Market Scenario by Region
3.1 Global Virus-like Particles (VLPs) Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Virus-like Particles (VLPs) Vaccine Global Virus-like Particles (VLPs) Vaccine Sales by Region: 2018-2029
3.2.1 Global Virus-like Particles (VLPs) Vaccine Sales by Region: 2018-2023
3.2.2 Global Virus-like Particles (VLPs) Vaccine Sales by Region: 2024-2029
3.3 Global Virus-like Particles (VLPs) Vaccine Global Virus-like Particles (VLPs) Vaccine Revenue by Region: 2018-2029
3.3.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Region: 2018-2023
3.3.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Region: 2024-2029
3.4 North America Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.4.1 North America Virus-like Particles (VLPs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Virus-like Particles (VLPs) Vaccine Sales by Country (2018-2029)
3.4.3 North America Virus-like Particles (VLPs) Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.5.1 Europe Virus-like Particles (VLPs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2018-2029)
3.5.3 Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Virus-like Particles (VLPs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Virus-like Particles (VLPs) Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Virus-like Particles (VLPs) Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.7.1 Latin America Virus-like Particles (VLPs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Virus-like Particles (VLPs) Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Virus-like Particles (VLPs) Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Virus-like Particles (VLPs) Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Virus-like Particles (VLPs) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Virus-like Particles (VLPs) Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Virus-like Particles (VLPs) Vaccine Sales by Type (2018-2029)
4.1.1 Global Virus-like Particles (VLPs) Vaccine Sales by Type (2018-2023)
4.1.2 Global Virus-like Particles (VLPs) Vaccine Sales by Type (2024-2029)
4.1.3 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2018-2029)
4.2.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2018-2023)
4.2.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2024-2029)
4.2.3 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Virus-like Particles (VLPs) Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Virus-like Particles (VLPs) Vaccine Sales by Application (2018-2029)
5.1.1 Global Virus-like Particles (VLPs) Vaccine Sales by Application (2018-2023)
5.1.2 Global Virus-like Particles (VLPs) Vaccine Sales by Application (2024-2029)
5.1.3 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2018-2029)
5.2.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2018-2023)
5.2.2 Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2024-2029)
5.2.3 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Virus-like Particles (VLPs) Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck and Co.
6.1.1 Merck and Co. Corporation Information
6.1.2 Merck and Co. Description and Business Overview
6.1.3 Merck and Co. Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck and Co. Virus-like Particles (VLPs) Vaccine Product Portfolio
6.1.5 Merck and Co. Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Virus-like Particles (VLPs) Vaccine Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Dynavax Technologies
6.4.1 Dynavax Technologies Corporation Information
6.4.2 Dynavax Technologies Description and Business Overview
6.4.3 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Product Portfolio
6.4.5 Dynavax Technologies Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sanofi Virus-like Particles (VLPs) Vaccine Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Wantai BioPharm
6.6.1 Wantai BioPharm Corporation Information
6.6.2 Wantai BioPharm Description and Business Overview
6.6.3 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Product Portfolio
6.6.5 Wantai BioPharm Recent Developments/Updates
6.7 Serum Institute of India
6.6.1 Serum Institute of India Corporation Information
6.6.2 Serum Institute of India Description and Business Overview
6.6.3 Serum Institute of India Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Serum Institute of India Virus-like Particles (VLPs) Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
6.8 Bharat Biotech
6.8.1 Bharat Biotech Corporation Information
6.8.2 Bharat Biotech Description and Business Overview
6.8.3 Bharat Biotech Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bharat Biotech Virus-like Particles (VLPs) Vaccine Product Portfolio
6.8.5 Bharat Biotech Recent Developments/Updates
6.9 LG Chem
6.9.1 LG Chem Corporation Information
6.9.2 LG Chem Description and Business Overview
6.9.3 LG Chem Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 LG Chem Virus-like Particles (VLPs) Vaccine Product Portfolio
6.9.5 LG Chem Recent Developments/Updates
6.10 VBI Vaccines
6.10.1 VBI Vaccines Corporation Information
6.10.2 VBI Vaccines Description and Business Overview
6.10.3 VBI Vaccines Virus-like Particles (VLPs) Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 VBI Vaccines Virus-like Particles (VLPs) Vaccine Product Portfolio
6.10.5 VBI Vaccines Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Virus-like Particles (VLPs) Vaccine Industry Chain Analysis
7.2 Virus-like Particles (VLPs) Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Virus-like Particles (VLPs) Vaccine Production Mode & Process
7.4 Virus-like Particles (VLPs) Vaccine Sales and Marketing
7.4.1 Virus-like Particles (VLPs) Vaccine Sales Channels
7.4.2 Virus-like Particles (VLPs) Vaccine Distributors
7.5 Virus-like Particles (VLPs) Vaccine Customers
8 Virus-like Particles (VLPs) Vaccine Market Dynamics
8.1 Virus-like Particles (VLPs) Vaccine Industry Trends
8.2 Virus-like Particles (VLPs) Vaccine Market Drivers
8.3 Virus-like Particles (VLPs) Vaccine Market Challenges
8.4 Virus-like Particles (VLPs) Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer